Health care stocks decreased late Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each easing about 0.2%.
The iShares Biotechnology ETF (IBB) fell 0.8%.
In corporate news, Teleflex (TFX) agreed to buy most of Biotronik's Vascular Intervention business for 760 million euros ($793.1 million) in cash. Teleflex also said it plans to separate its urology, acute care, and OEM segments into a publicly traded company. Teleflex shares slumped past 21%.
GSK (GSK) said it will stop setting diversity targets, citing US legal concerns amid President Donald Trump's executive orders rolling back federal diversity, equity, and inclusion programs. GSK shares were easing 0.2%.
A buyout of Walgreens Boots Alliance (WBA) would set the stage for a three-way split of the company, with Executive Chair Stefano Pessina keeping a notable stake under the agreement, the Financial Times reported. Walgreens shares rose 1.5%.
Cassava Sciences (SAVA) jumped past 13%. The firm said it has signed a license agreement with Yale University for intellectual property rights, including rights to an issued US method of treatment patent for potential treatment with simufilam of seizures related to rare neurodevelopmental disorders.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。